Freespira produces Freespira, an FDA-cleared digital therapeutic proven to reduce or eliminate panic attack, panic disorder and PTSD symptoms in 28 days through a respiratory-normalization protocol. The company offers an at-home, drug-free, evidence-based solution and markets to health plans, self-insured employers and the Veterans Administration. Multiple peer-reviewed trials reported strong outcomes: a VA trial showed significant PTSD severity reductions in 85% of subjects post-treatment (50% remission at six months, 84% patient satisfaction, 77% adherence); a multi-center trial found clinically significant panic symptom reduction in 82% of subjects at 12 months (84% adherence, 88% satisfaction); and an Allegheny Health Network study reported 91% of patients with significant symptom reduction at 12 months plus substantial insurance cost savings. The company changed its name from Palo Alto Health Sciences to Freespira, Inc. to reflect its mission to improve quality of life and reduce medical spend. Freespira has announced plans to commercialize broadly and expand access among veterans, first responders, frontline healthcare workers, employers and payors.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2020